Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine effects on brain morphometry in knee osteoarthritis
NCT01558700Phase 4
Key facts
- Status
- Completed
- Start
- Mar 2012
- Primary completion
- Apr 2014
- Countries
- 1
- Sponsor
- Northwestern University
- Modality
- Small Molecules
- Drugs
- duloxetine
- Conditions
- osteoarthritis (OA)
01
Overview
Phase 4, randomised, double-blind trial of duloxetine in osteoarthritis (OA) (2 arms), sponsored by Northwestern University. Primary endpoint: Change in Brain Gray Matter Volume at 16 weeks. Started Mar 2012; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Duloxetine
Duloxetine 30mg/day (1 wk) -> 60mg/day (15 wks) -> 30mg/day (1 wk)
Sugar pill
Matching placebo capsule once daily for 17 weeks
03
Who it enrols
Patients 45-80 years old with knee OA for at least 12 months and VAS pain >5/10. Excludes diabetes, major depressive disorder, and MRI contraindications.
04
Endpoints
Primary
Change in Brain Gray Matter Volume
Secondary
Change in Pain Magnitude
Beyond the preview
Go deeper on NCT01558700.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01558700.